Risk assessment of over-the-counter cannabinoid-based cosmetics: Legal and regulatory issues governing the safety of cannabinoid-based cosmetics in the UAE
Contents
Appearance
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C25H29N3O3 |
Molar mass | 419.525 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Adimolol (developmental code name MEN-935) is antihypertensive agent which acts as a non-selective α1-, α2-, and β-adrenergic receptor antagonist.[1]
Synthesis
The reaction between 1-naphthyl glycidyl ether (1) and 3-(3-amino-3-methylbutyl)-1H-benzimidazol-2-one (2) gives adimolol (3).[2][3]
References
- ^ Palluk R, Hoefke W, Gaida W, Mierau J, Bechtel WD (July 1986). "Interactions of MEN 935 (adimolol), a long acting beta- and alpha-adrenolytic antihypertensive agent, with postsynaptic alpha-adrenoceptors in different isolated blood vessels--influence of angiotensin II". Naunyn-Schmiedeberg's Archives of Pharmacology. 333 (3): 277–83. doi:10.1007/bf00512941. PMID 3020439. S2CID 24300936.
- ^ Hoefke W, Gaida W, Palluk R, Mentrup A (1986). "Adimolol Hydrochloride Hydrate". Drugs of the Future. 11: 9. doi:10.1358/dof.1986.011.01.62036.
- ^ US 4255430, Koppe H, Mentrup A, Renth EO, Schromm K, Hoefke W, Muacevic G, issued 1981, assigned to Boehringer Ingelheim Gmbh